Skip to main content

CORRECTION article

Front. Immunol., 15 November 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1334733
This article is part of the Research Topic Identifying and developing novel therapeutic targets for multiple myeloma treatment View all 6 articles

Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma

This article is a correction to:

  1. Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma

    1. Read original article
Hong Phuong NguyenHong Phuong Nguyen1Anh Quynh LeAnh Quynh Le1Enze Liu,Enze Liu2,3Annamaria CesaranoAnnamaria Cesarano4Francesco DiMeo&#x;Francesco DiMeo4†Fabiana Perna&#x;Fabiana Perna4†Reuben KapurReuben Kapur1Brian A. Walker,Brian A. Walker2,3Ngoc Tung Tran*Ngoc Tung Tran1*
  • 1Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana School of Medicine, Indianapolis, IN, United States
  • 2Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, United States
  • 3Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, United States
  • 4Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States

A Corrigendum on
Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma

by Nguyen HP, Le AQ, Liu E, Cesarano A, DiMeo F, Perna F, Kapur R, Walker BA and Tran NT (2023). Front. Immunol. 14:1239614. doi: 10.3389/fimmu.2023.1239614

In the published article, there was an error in affiliation 1. Instead of “Well Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States”, it should be “Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana School of Medicine, Indianapolis, United States.”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: multiple myeloma, PRMT1, targeted therapy, relapsed/refractory myeloma, xenograft model

Citation: Nguyen HP, Le AQ, Liu E, Cesarano A, DiMeo F, Perna F, Kapur R, Walker BA and Tran NT (2023) Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma. Front. Immunol. 14:1334733. doi: 10.3389/fimmu.2023.1334733

Received: 07 November 2023; Accepted: 10 November 2023;
Published: 15 November 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Nguyen, Le, Liu, Cesarano, DiMeo, Perna, Kapur, Walker and Tran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ngoc Tung Tran, tungtran@iu.edu

†Present address: Francesco DiMeo, Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United States
Fabiana Perna, Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.